Advertisement

Prevention of Transmission of Virus Infections by Blood Transfusions and Removal of Virus Infectivity from Clotting Factor Concentrates

  • R. J. Gerety
Part of the Developments in Hematology and Immunology book series (DIHI, volume 13)

Abstract

Virus infections are serious complications following blood transfusions or intravenous therapy with clotting factor concentrates. Hepatitis A virus (HAV) is rarely transmitted by blood and never by plasma derivatives. Hepatitis A is characterized by a short viremia which most often coincides with clinical illness. In addition neutralizing antibodies to HAV are present in all plasma pools from which clotting factor concentrates are manufactured (1). Chronic Hepatitis B and non-A non-B hepatitis commonly follow acute infections (5 to 10% for hepatitis B, more than 40% and perhaps close to 100% for non-A non-B hepatitis). Chronic infections with hepatitis B virus (HBV) are characterized by serum levels of infectious virus up to 108/ml (infectious units) while levels of infectious non-A non-B virus are generally in the range of 102/ml (2,3). Little has been published concerning levels of HTLV III in blood or plasma.

Keywords

Clotting Factor Plasma Protein Fraction Plasma Derivative Normal Human Serum Albumin Clotting Factor Concentrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Small wood LA, Tabor E, Finlayson JS, Gerety RJ. Antibodies to Hepatitis A virus in immune serum globulin. Lancet, 1980;ii:482–3.CrossRefGoogle Scholar
  2. 2.
    Baker LF, Maynard JE, Purcell RH, et al. Hepatitis B virus infection in chimpanzees: Titration of subtypes. J Infect Dis 1975; 132: 451–7.CrossRefGoogle Scholar
  3. 3.
    Tabor E. Propagation of hepatitis viruses in vivo and in vitro: Viral Hepatitis: Second International Max von Pettenkofer Symposium, Overby LR, Deinhardt F, Deinhardt J, Dekker M, ed. New York 1983: 57–9.Google Scholar
  4. 4.
    Trepo C, Hantz O, Jacquier MF, Nemoz G, Cappel R, Trepo D. Different fates of hepatitis B virus markers during plasma fractionation. Vox Sang 1978; 35: 142–8.CrossRefGoogle Scholar
  5. 5.
    Gerety RJ, Eyster ME. Hepatitis among hemophiliacs. In: Gerety RJ ed. Non-A, Non-B Hepatitis. New York, Academic Press 1981: 97–117.Google Scholar
  6. 6.
    Einarrson M. Studies on the hepatitis B virus. Isolation of hepatitis B surface antigen from human serum and removal of hepatitis B virus from blood products. Doctoral thesis; Uppsala University, KabiVitrum AB, 112 87 Stockholm, Sweden 1983.Google Scholar
  7. 7.
    Tabor E, Aronson DL, Gerety RJ. Removal of hepatitis-B-virus infectivity from factor IX complex by hepatitis-B-immune globulin. Lancet 1980; ii: 68–70.CrossRefGoogle Scholar
  8. 8.
    Murray R. Viral hepatitis Bull. N.Y. Acad. Med, 1985; 31: 341–58.Google Scholar
  9. 9.
    Prince AM, Stephan W, Brotman B, van den Ende MC. Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma in hepatitis transmission by factor IX complex in chimpanzees. Thromb Haemost, 1980; 44: 138–42.PubMedGoogle Scholar
  10. 10.
    Gellis SS, Neefe JR, Stokes J, Strong LE, Janeway CA, Scatchard G. Chemical, clinical and immunological studies on the products of human plasma fractionation XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948; 27: 239–44.CrossRefGoogle Scholar
  11. 11.
    Murray R, Diefenbach WCI. Effect of heat on the agent of homologous serum hepatitis. Proc. Soc. Exp. Biol. Med. 1953; 84: 230–1.PubMedGoogle Scholar
  12. 12.
    Tabor E, Gerety RJ. The chimpanzee animal model for non-A, non-B hepatitis: New application. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Phila.: Franklin Institute Press, 1982: 305 - 17.Google Scholar
  13. 13.
    Seto B, Coleman Jr. WG, Iwarson S, Gerety RJ. Detection of reverse transcriptase activity in association with the non-A, non-B hepatitis agent(s). Lancet 1984;ii:941–3.Google Scholar
  14. 14.
    Soulier JP, Blatix C, Courouce AM, Benamon D, Amouch P, Drouet J. Prevention of virus B hepatitis ( SH hepatitis ). A J Dis Child, 1972: 429–34.Google Scholar
  15. 15.
    Tabor E, Murano G, Snoy P, Gerety RJ. Inactivation of hepatitis B virus by heat in antithrombin III stabilized with citrate. Thromb Res 1981; 22: 233–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Heimburger N, Schwinn H, Gratz P, Luben G, Kumpe G, Herchenhan B. Factor VIII-Konzentrat, hochgereinigt und in losung erhitzt. Arzneimittelforsch 1981; 31: 619–22.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • R. J. Gerety

There are no affiliations available

Personalised recommendations